AngioDynamics Boosts FY26 Outlook for Third Straight Quarter on 19% Med Tech Sales Growth
Summary
AngioDynamics reported strong fiscal Q3 2026 results, with net sales increasing 8.9% to $78.4 million and its Med Tech segment growing 19.0% to $37.3 million. The company also significantly reduced its adjusted loss per share to $0.07 from $0.08 in the prior year, alongside achieving positive adjusted EBITDA of $1.8 million. Crucially, this marks the third consecutive quarter the company has raised its full-year FY2026 guidance for both net sales and adjusted EBITDA. This sustained positive performance, particularly in the high-growth Med Tech segment, indicates a strong operational trajectory and improved profitability, building on the positive Q2 results. Traders would view this as a significant positive catalyst, suggesting continued momentum and potential for further upside. Investors will be watching for continued execution on the updated guidance and further expansion of its Med Tech portfolio.
At the time of this announcement, ANGO was trading at $12.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $492.1M. The 52-week trading range was $8.36 to $13.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.